Apimeds Pharmaceuticals' subsidiary, MindWave Innovations, secured a 12-month technology services agreement with AQUAE Holdings to build and operate AQUAEChain, a platform for ALCI Credits. This deal provides MindWave with contracted fees and a recurring 20% allocation of ALCI Credits, significantly expanding its digital asset footprint and driving a substantial surge in APUS stock.
Apimeds Pharmaceuticals (APUS) shares skyrocketed following the announcement that its subsidiary, MindWave Innovations, secured a significant 12-month technology services agreement with AQUAE Holdings. MindWave will build and operate AQUAEChain, a platform for ecosystem-finance ALCI Credits, earning contracted fees and a 20% allocation of these credits. This deal is a major commercial expansion for MindWave's digital asset footprint, particularly ahead of its MindChain mainnet launch, and signals a new revenue stream and strategic direction for the company. For traders, this represents a strong short-term positive catalyst for APUS, with potential long-term implications if the AQUAEChain platform proves successful and the five-year extension option is exercised, diversifying Apimeds' business beyond traditional pharmaceuticals.